Tangle between regulation and politics makes uncomfortable viewing from industry
I’m going to write about mifepristone and the legal troubles around it, and I will probably regret doing so. That’s partly because the situation is changing – this dispute is now before the US Supreme Court, and for better or worse, they will have the last word. But as of this writing, that last word hasn’t been handed down, and it’s unclear when it will be (although it should be soon).